NASDAQ · KRON
Healthcare · Biotechnology
$0.88
Up+$0.01 (+1.49%)
Updated Aug 24, 2026, 2:36 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
KRON does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning KRON.
KRON research
Company profile and research snapshot.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 14, 2024 | Piper Sandler | Neutral | — |
| Nov 14, 2024 | TD Cowen | Hold | — |
| Oct 8, 2024 | Piper Sandler | Overweight | — |
| Aug 19, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 1, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 18, 2025
Halper Sadeh LLC is investigating several companies, including American Axle & Manufacturing Holdings, Kronos Bio, ProAssurance, and SpringWorks Therapeutics, for potential violations of securities laws and breaches of fiduciary duties to shareholders.
GlobeNewswire Inc. · May 17, 2025
Monteverde & Associates PC, a top 50 M&A class action firm, is investigating several proposed mergers, including ProAssurance Corporation, Kronos Bio, American Axle & Manufacturing Holdings, and SpringWorks Therapeutics.
Benzinga · May 16, 2025
The M&A Class Action Firm is investigating the proposed mergers of ProAssurance Corporation, Kronos Bio, Inc., American Axle & Manufacturing Holdings, Inc., and SpringWorks Therapeutics, Inc. with other companies.
Benzinga · May 1, 2025
Kronos Bio has entered into a definitive merger agreement to be acquired by Concentra Biosciences for $0.57 in cash per share plus a contingent value right. The transaction is expected to close in mid-2025.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KRON.
No results
No recent SID articles mention KRON.
